Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

Clinical trial NCT02402660 · ENROLLING_BY_INVITATION

Trial details

NCT number: NCT02402660
Sponsor: Alkeus Pharmaceuticals, Inc.
Status: ENROLLING_BY_INVITATION
Phase: Phase 2
Study type: INTERVENTIONAL

Stargardt Disease Stargardt Macular Degeneration Stargardt Macular Dystrophy Autosomal Recessive Stargardt Disease 1 (ABCA4-related)

Start date: 2015-08-01
Primary completion: 2026-06-30
Enrollment: 160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.